Evoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025

Reuters

2025/11/13

<a href="https://laohu8.com/S/EVOK">Evoke Pharma</a> Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025

Overview

Evoke Q3 2025 net product sales rose 61% yr/yr to $4.3 mln
Company to be acquired by QOL Medical for $11.00 per share
Gimoti patent extended to November 2038, ensuring exclusivity

Outlook

Company expects acquisition by QOL Medical to close in Q4 2025
Company anticipates expanded distribution through new pharmacy relationships
Company believes acquisition will enhance growth potential under new leadership

Result Drivers

SALES GROWTH - Net product sales for Q3 2025 increased by 61% yr/yr, driven by expanded pharmacy access and distribution partnerships
EXPANDED ACCESS - New pharmacy relationships with Omnicell and Brentwood Pharmacy enhance distribution

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$0.45
Q3 Net Income		-$1.20 mln
Q3 Operating Expenses		$5.40 mln

Analyst Coverage

The one available analyst rating on the shares is "hold"
The average consensus recommendation for the pharmaceuticals peer group is "buy."

Press Release: ID:nGNX80pkz3

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2583556248"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583556248\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583556248?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 20:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583556248","market":"nz","top_or_hot":-1,"title":"Evoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/EVOK\">Evoke Pharma</a> Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025</title></head><body><p><span>Overview</span></p><ul><li><p>Evoke Q3 2025 net product sales rose 61% yr/yr to $4.3 mln</p></li><li><p>Company to be acquired by QOL Medical for $11.00 per share</p></li><li><p>Gimoti patent extended to November 2038, ensuring exclusivity</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects acquisition by QOL Medical to close in Q4 2025</p></li><li><p>Company anticipates expanded distribution through new pharmacy relationships</p></li><li><p>Company believes acquisition will enhance growth potential under new leadership</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>SALES GROWTH - Net product sales for Q3 2025 increased by 61% yr/yr, driven by expanded pharmacy access and distribution partnerships</p></li><li><p>EXPANDED ACCESS - New pharmacy relationships with <a href=\"https://laohu8.com/S/OMCL\">Omnicell</a> and Brentwood Pharmacy enhance distribution</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.45</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$1.20 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$5.40 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"hold\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"</p></li></ul><p>Press Release: <span>ID:nGNX80pkz3</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Evoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEvoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-13 20:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/EVOK\">Evoke Pharma</a> Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025</title></head><body><p><span>Overview</span></p><ul><li><p>Evoke Q3 2025 net product sales rose 61% yr/yr to $4.3 mln</p></li><li><p>Company to be acquired by QOL Medical for $11.00 per share</p></li><li><p>Gimoti patent extended to November 2038, ensuring exclusivity</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects acquisition by QOL Medical to close in Q4 2025</p></li><li><p>Company anticipates expanded distribution through new pharmacy relationships</p></li><li><p>Company believes acquisition will enhance growth potential under new leadership</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>SALES GROWTH - Net product sales for Q3 2025 increased by 61% yr/yr, driven by expanded pharmacy access and distribution partnerships</p></li><li><p>EXPANDED ACCESS - New pharmacy relationships with <a href=\"https://laohu8.com/S/OMCL\">Omnicell</a> and Brentwood Pharmacy enhance distribution</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.45</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$1.20 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$5.40 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"hold\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"</p></li></ul><p>Press Release: <span>ID:nGNX80pkz3</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EVOK","symbol_name":"Evoke Pharma Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nL1N3WP0GH:1","article_id":"2583556248","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583556248","pubTimestamp":1763036065,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Evoke Pharma Q3 sales rise 61%, expects QOL Medicalacquisition to close in Q4 2025OverviewEvoke Q3 2025 net product sales rose 61% yr/yr to $4.3 mlnCompany to be acquired by QOL Medical for $11.00 per","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EVOK":"Evoke Pharma Inc.","BK4007":"制药"},"translate_title":"Evoke Pharma第三季度销售额增长61%，预计QOL Medical收购将于2025年第四季度完成","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVOK":0.9},"content_text":"Evoke Pharma Q3 sales rise 61%, expects QOL Medical acquisition to close in Q4 2025OverviewEvoke Q3 2025 net product sales rose 61% yr/yr to $4.3 mlnCompany to be acquired by QOL Medical for $11.00 per shareGimoti patent extended to November 2038, ensuring exclusivityOutlookCompany expects acquisition by QOL Medical to close in Q4 2025Company anticipates expanded distribution through new pharmacy relationshipsCompany believes acquisition will enhance growth potential under new leadershipResult DriversSALES GROWTH - Net product sales for Q3 2025 increased by 61% yr/yr, driven by expanded pharmacy access and distribution partnershipsEXPANDED ACCESS - New pharmacy relationships with Omnicell and Brentwood Pharmacy enhance distributionKey DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$0.45Q3 Net Income-$1.20 mlnQ3 Operating Expenses$5.40 mlnAnalyst CoverageThe one available analyst rating on the shares is \"hold\"The average consensus recommendation for the pharmaceuticals peer group is \"buy.\"Press Release: ID:nGNX80pkz3For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}